Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice

EMBO Reports

Volumn 17, Issue 4, 2016, Pages 530-551

  Maeda, Sumihiro ^a,b   Djukic, Biljana ^a   Taneja, Praveen ^a   Yu, Gui Qiu ^a   Lo, Iris ^a   Davis, Allyson ^a   Craft, Ryan ^a   Guo, Weikun ^a   Wang, Xin ^a   Kim, Daniel ^a   Ponnusamy, Ravikumar ^a,e   Gill, T Michael ^a   Masliah, Eliezer ^c,d   Mucke, Lennart ^a,b  

^a GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

A152T; Alzheimer's disease; frontotemporal dementia; hyperexcitability; tau

Indexed keywords

A152T PROTEIN; AMYLOID PRECURSOR PROTEIN; MESSENGER RNA; PROTEIN VARIANT; TAU PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR DISORDER; BRAIN ELECTROPHYSIOLOGY; BRAIN SLICE; BRAIN TISSUE; CELL LOSS; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTROENCEPHALOGRAM; ELECTROSTIMULATION; ELEVATED PLUS MAZE TEST; EPILEPTIC DISCHARGE; EPILEPTOGENESIS; EXPLORATORY BEHAVIOR; GENE EXPRESSION; LEARNING DISORDER; MEMORY; MORRIS WATER MAZE TEST; MOTOR PERFORMANCE; MOUSE; NERVE CELL; NERVE CELL DEGENERATION; NERVE STIMULATION; NESTING; NEUROPATHOLOGY; NONHUMAN; OPEN FIELD TEST; POLE TEST; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; ROTAROD TEST; SOCIAL APPROACH TEST; SPATIAL LEARNING; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE; AGING; ALZHEIMER DISEASE; ANIMAL; BRAIN; CHEMISTRY; DISEASE MODEL; FRONTOTEMPORAL DEMENTIA; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TAUOPATHY;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; COGNITIVE DYSFUNCTION; DISEASE MODELS, ANIMAL; FRONTOTEMPORAL DEMENTIA; HUMANS; MICE; MICE, TRANSGENIC; NEURONS; TAU PROTEINS; TAUOPATHIES;

EID: 84959518689     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.15252/embr.201541438     Document Type: Article

References (99)

1. Morris M, Maeda S, Vossel K, Mucke L, (2011) The many faces of tau. Neuron 70: 410-426
2. Huang Y, Mucke L, (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148: 1204-1222
3. Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM, Lee VM, Trojanowski JQ, (2015) Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol 129: 469-491
4. Lee VM, Goedert M, Trojanowski JQ, (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24: 1121-1159
5. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM, (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261: 6084-6089
6. Kosik KS, Joachim CL, Selkoe DJ, (1986) Microtubule-associated protein tau (t) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 83: 4044-4048
7. Kondo J, Honda T, Mori H, Hamada Y, Miura R, Ogawara M, Ihara Y, (1988) The carboxyl third of tau is tightly bound to paired helical filaments. Neuron 1: 827-834
8. Nukina N, Ihara Y, (1986) One of the antigenic determinants of paired helical filaments is related to tau protein. J Biochem 99: 1541-1544
9. Wood JG, Mirra SS, Pollock NJ, Binder LI, (1986) Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (t). Proc Natl Acad Sci USA 83: 4040-4043
10. Lee VM, Balin BJ, Otvos L Jr, Trojanowski JQ, (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251: 675-678
11. Braak H, Braak E, (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259
12. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, Morrison JH, Gold G, Hof PR, (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60: 1495-1500
13. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, et al, (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8: 1-13
14. Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, Lobach I, Karydas A, Voltarelli L, Scherling C, Heuer H, et al, (2015) Divergent CSF tau alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 86: 244-250
15. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, et al, (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79: 1094-1108
16. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC, (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34: 457-468
17. Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, et al, (2014) Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 137: 1762-1771
18. Reed LA, Wszolek ZK, Hutton M, (2001) Phenotypic correlations in FTDP-17. Neurobiol Aging 22: 89-107
19. Boeve BF, Hutton M, (2008) Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). Arch Neurol 65: 460-464
20. Goedert M, Ghetti B, Spillantini MG, (2012) Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med 2: a006254
21. Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, et al, (2014) Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83: 253-260
22. Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, et al, (2014) Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82: 1271-1288
23. Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R, et al, (2012) Evidence for a role of the rare p. A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet 21: 3500-3512
24. Kara E, Ling H, Pittman AM, Shaw K, de Silva R, Simone R, Holton JL, Warren JD, Rohrer JD, Xiromerisiou G, et al, (2012) The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. Neurobiol Aging 33: 2231 e7-2231 e14.
25. Lee SE, Tartaglia MC, Yener G, Genc S, Seeley WW, Sanchez-Juan P, Moreno F, Mendez MF, Klein E, Rademakers R, et al, (2013) Neurodegenerative disease phenotypes in carriers of MAPT p. A152T, a risk factor for frontotemporal dementia spectrum disorders and Alzheimer disease. Alzheimer Dis Assoc Disord 27: 302-309
26. Kovacs GG, Wohrer A, Strobel T, Botond G, Attems J, Budka H, (2011) Unclassifiable tauopathy associated with an A152T variation in MAPT exon 7. Clin Neuropathol 30: 3-10
27. Klopotowska D, Strzadala L, Matuszyk J, (2008) Inducibility of doxycycline-regulated gene in neural and neuroendocrine cells strongly depends on the appropriate choice of a tetracycline-responsive promoter. Neurochem Int 52: 221-229
28. Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER, (1996) Control of memory formation through regulated expression of a CaMKII transgene. Science 274: 1678-1683
29. Harris JA, Koyama A, Maeda S, Ho K, Devidze N, Dubal DB, Yu G-Q, Masliah E, Mucke L, (2012) Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS One 7: e45881
30. Barten DM, Cadelina GW, Hoque N, DeCarr LB, Guss VL, Yang L, Sankaranarayanan S, Wes PD, Flynn ME, Meredith JE, et al, (2011) Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. J Alzheimers Dis 24 (Suppl 2): 127-141
31. SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, et al, (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309: 476-481
32. Delerue F, White M, Ittner LM, (2014) Inducible, tightly regulated and non-leaky neuronal gene expression in mice. Transgenic Res 23: 225-233
33. West MJ, Coleman PD, Flood DG, Troncoso JC, (1994) Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 344: 769-772
34. Otvos L Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM, (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 39: 669-673
35. Porzig R, Singer D, Hoffmann R, (2007) Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein. Biochem Biophys Res Commun 358: 644-649
36. Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E, et al, (2011) Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci 31: 2511-2525
37. Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, Miyasaka T, Murayama S, Ikai A, Takashima A, (2007) Granular tau oligomers as intermediates of tau filaments. Biochemistry 46: 3856-3861
38. Weaver CL, Espinoza M, Kress Y, Davies P, (2000) Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging 21: 719-727
39. Cunningham C, Deacon R, Wells H, Boche D, Waters S, Diniz CP, Scott H, Rawlins JN, Perry VH, (2003) Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease. Eur J Neurosci 17: 2147-2155
40. Lin L, Chen G, Kuang H, Wang D, Tsien JZ, (2007) Neural encoding of the concept of nest in the mouse brain. Proc Natl Acad Sci USA 104: 6066-6071
41. Heller HC, Salehi A, Chuluun B, Das D, Lin B, Moghadam S, Garner CC, Colas D, (2014) Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors. Neurobiol Learn Mem 116: 162-171
42. Han HJ, Allen CC, Buchovecky CM, Yetman MJ, Born HA, Marin MA, Rodgers SP, Song BJ, Lu HC, Justice MJ, et al, (2012) Strain background influences neurotoxicity and behavioral abnormalities in mice expressing the tetracycline transactivator. J Neurosci 32: 10574-10586
43. Abbott LF, Regehr WG, (2004) Synaptic computation. Nature 431: 796-803
44. Zucker RS, Regehr WG, (2002) Short-term synaptic plasticity. Annu Rev Physiol 64: 355-405
45. Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, et al, (2013) Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol 70: 1158-1166
46. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu G-Q, Palop JJ, et al, (2012) Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci USA 109: E2895-E2903
47. Palop JJ, Mucke L, (2010) Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 13: 812-818
48. Palop JJ, Mucke L, (2009) Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66: 435-440
49. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu G-Q, Kreitzer A, et al, (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55: 697-711
50. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu G-Q, et al, (2011) Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 31: 700-711
51. Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, et al, (2012) Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149: 708-721
52. Suberbielle E, Sanchez PE, Kravitz AV, Wang X, Ho K, Eilertson K, Devidze N, Kreitzer AC, Mucke L, (2013) Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-β. Nat Neurosci 16: 613-621
53. Orr AG, Hsiao EC, Wang MM, Ho K, Kim DH, Wang X, Guo W, Kang J, Yu GQ, Adame A, et al, (2015) Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory. Nat Neurosci 18: 423-434
54. 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20: 4050-4058
55. Chin J, Palop JJ, Puoliväli J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L, (2005) Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 25: 9694-9703
56. Chin J, Palop JJ, Yu G-Q, Kojima N, Masliah E, Mucke L, (2004) Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci 24: 4692-4697
57. Labbe C, Ogaki K, Lorenzo-Betancor O, Soto-Ortolaza AI, Walton RL, Rayaprolu S, Fujioka S, Murray ME, Heckman MG, McCarthy A, et al, (2015) Role for the microtubule-associated protein tau variant p.A152T in risk of alpha-synucleinopathies. Neurology 85: 1680-1686
58. Desikan RS, Schork AJ, Wang Y, Witoelar A, Sharma M, McEvoy LK, Holland D, Brewer JB, Chen CH, Thompson WK, et al, (2015) Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol Psychiatry 20: 1588-1595
59. Monti G, Meletti S, (2015) Emotion recognition in temporal lobe epilepsy: a systematic review. Neurosci Biobehav Rev 55: 280-293
60. Fong H, Wang C, Knoferle J, Walker D, Balestra ME, Tong LM, Leung L, Ring KL, Seeley WW, Karydas A, et al, (2013) Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell Rep 1: 226-234
61. Wang Y, Martinez-Vicente M, Kruger U, Kaushik S, Wong E, Mandelkow EM, Cuervo AM, Mandelkow E, (2009) Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet 18: 4153-4170
62. de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT, (2010) Caspase activation precedes and leads to tangles. Nature 464: 1201-1204
63. LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI, Brady ST, (2009) The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J Neurosci Res 87: 440-451
64. Quintanilla RA, Matthews-Roberson TA, Dolan PJ, Johnson GV, (2009) Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. J Biol Chem 284: 18754-18766
65. 45-230 transgenic mice. Neuroscience 275: 322-339
66. Hochgrafe K, Sydow A, Mandelkow EM, (2013) Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology. FEBS J 280: 4371-4381
67. Devos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR, Schuler DR, Maloney SE, Wozniak DF, Rigo F, et al, (2013) Antisense reduction of tau in adult mice protects against seizures. J Neurosci 33: 12887-12897
68. Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, Laenen I, Geerts H, Mercken M, Sciot R, Van Lommel A, et al, (1999) Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 155: 2153-2165
69. Probst A, Götz J, Wiederhold KH, Tolnay M, Mistl C, Jaton AL, Hong M, Ishihara T, Lee VMY, Trojanowski JQ, et al, (2000) Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (Berl) 99: 469-481
70. Zhang B, Higuchi M, Yoshiyama Y, Ishihara T, Forman MS, Martinez D, Joyce S, Trojanowski JQ, Lee VM, (2004) Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J Neurosci 24: 4657-4667
71. Kimura T, Yamashita S, Fukuda T, Park JM, Murayama M, Mizoroki T, Yoshiike Y, Sahara N, Takashima A, (2007) Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tau. EMBO J 26: 5143-5152
72. Götz J, Probst A, Spillantini MG, Schäfer T, Jakes R, Bürki K, Goedert M, (1995) Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 14: 1304-1313
73. Duff K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M, Malester B, Hutton M, Adamson J, Goedert M, et al, (2000) Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis 7: 87-98
74. Decker JM, Kruger L, Sydow A, Dennissen F, Siskova Z, Mandelkow E, Mandelkow EM, (2016) The Tau/A152T mutation, a risk factor for frontotemporal spectrum disorders, leads to NR2B receptor-mediated excitotoxicity. EMBO Rep 17: 552-569
75. Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G, (1998) Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci 111 (Pt 21): 3167-3177
76. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, et al, (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142: 387-397
77. Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, Ward S, Reyes JF, Philibert K, Glucksman MJ, et al, (2011) Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem 286: 23063-23076
78. Van der Jeugd A, Hochgrafe K, Ahmed T, Decker JM, Sydow A, Hofmann A, Wu D, Messing L, Balschun D, D'Hooge R, et al, (2012) Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol 123: 787-805
79. Chong SA, Benilova I, Shaban H, De Strooper B, Devijver H, Moechars D, Eberle W, Bartic C, Van Leuven F, Callewaert G, (2011) Synaptic dysfunction in hippocampus of transgenic mouse models of Alzheimer's disease: a multi-electrode array study. Neurobiol Dis 44: 284-291
80. Levenga J, Krishnamurthy P, Rajamohamedsait H, Wong H, Franke TF, Cain P, Sigurdsson EM, Hoeffer CA, (2013) Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments. Acta Neuropathol Commun 1: 34
81. Decker JM, Kruger L, Sydow A, Zhao S, Frotscher M, Mandelkow E, Mandelkow EM, (2015) Pro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca(++) dysregulation. Acta Neuropathol Commun 3: 23
82. Kumar S, Tepper K, Kaniyappan S, Biernat J, Wegmann S, Mandelkow EM, Muller DJ, Mandelkow E, (2014) Stages and conformations of the Tau repeat domain during aggregation and its effect on neuronal toxicity. J Biol Chem 289: 20318-20332
83. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu G-Q, Mucke L, (2007) Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316: 750-754
84. Holth JK, Bomben VC, Reed JG, Inoue T, Younkin L, Younkin SG, Pautler RG, Botas J, Noebels JL, (2013) Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J Neurosci 33: 1651-1659
85. Gheyara AL, Ponnusamy R, Djukic B, Craft RJ, Ho K, Guo W, Finucane MM, Sanchez PE, Mucke L, (2014) Tau reduction prevents disease in a mouse model of Dravet syndrome. Ann Neurol 76: 443-456
86. Garcia-Cabrero AM, Guerrero-Lopez R, Giraldez BG, Llorens-Martin M, Avila J, Serratosa JM, Sanchez MP, (2013) Hyperexcitability and epileptic seizures in a model of frontotemporal dementia. Neurobiol Dis 58: 200-208
87. Qizilbash N, Gregson J, Johnson ME, Pearce N, Douglas I, Wing K, Evans SJ, Pocock SJ, (2015) BMI and risk of dementia in two million people over two decades: a retrospective cohort study. Lancet Diabetes Endocrinol 3: 431-436
88. Morris M, Hamto P, Adame A, Devidze N, Masliah E, Mucke L, (2013) Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice. Neurobiol Aging 34: 1523-1529
89. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, et al, (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487-1491
90. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM, (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Ab and synaptic dysfunction. Neuron 39: 409-421
91. Grueninger F, Bohrmann B, Czech C, Ballard TM, Frey JR, Weidensteiner C, von Kienlin M, Ozmen L, (2010) Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiol Dis 37: 294-306
92. Platt B, Drever B, Koss D, Stoppelkamp S, Jyoti A, Plano A, Utan A, Merrick G, Ryan D, Melis V, et al, (2011) Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PLoS One 6: e27068
93. Seino Y, Kawarabayashi T, Wakasaya Y, Watanabe M, Takamura A, Yamamoto-Watanabe Y, Kurata T, Abe K, Ikeda M, Westaway D, et al, (2010) Amyloid beta accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau double-transgenic mouse model. J Neurosci Res 88: 3547-3554
94. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM, (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53: 337-351
95. Overk CR, Cartier A, Shaked G, Rockenstein E, Ubhi K, Spencer B, Price DL, Patrick C, Desplats P, Masliah E, (2014) Hippocampal neuronal cells that accumulate alpha-synuclein fragments are more vulnerable to Abeta oligomer toxicity via mGluR5-implications for dementia with Lewy bodies. Mol Neurodegener 9: 18
96. Gallyas F, (1971) Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol Acad Sci Hung 19: 1-8
97. Ting JT, Daigle TL, Chen Q, Feng G, (2014) Acute brain slice methods for adult and aging animals: application of targeted patch clamp analysis and optogenetics. Methods Mol Biol 1183: 221-242
98. Castillo PE, Weisskopf MG, Nicoll RA, (1994) The role of Ca2 + channels in hippocampal mossy fiber synaptic transmission and long-term potentiation. Neuron 12: 261-269
99. Calixto E, Thiels E, Klann E, Barrionuevo G, (2003) Early maintenance of hippocampal mossy fiber-long-term potentiation depends on protein and RNA synthesis and presynaptic granule cell integrity. J Neurosci 23: 4842-4849